Since MSC-TPr can efficiently uptake and process soluble OVA, yet are unable to activate CD8 T cells in vitro, we next interrogated their therapeutic utility against the E.G7 (OVA-expressing EL4 thymoma) T-cell lymphoma model (Figure 5A). This evidence concerns the gene CD8A and T-cell non-Hodgkin lymphoma.